查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1963885

支气管炎治疗市场－全球产业规模、份额、趋势、机会、预测：按药物类型、类别、最终用户、地区和竞争格局划分，2021-2031年

Bronchitis Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Class of Drugs, By Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

全球支气管炎治疗市场预计将从 2025 年的 85.7 亿美元成长到 2031 年的 116.9 亿美元，复合年增长率为 5.31%。

该领域涵盖多种旨在减轻支气管发炎和改善呼吸功能的药物，例如支气管扩张剂、抗发炎药物、抗生素和祛痰药。市场成长的主要驱动力是呼吸系统疾病盛行率的上升，而这又归因于全球人口老化、持续的烟草消费以及日益严重的环境污染。根据国际药学联合会2024年的数据，全球约有3.91亿人将患有慢性阻塞性肺病（COPD），这是一种以慢性支气管炎为主要特征的疾病，凸显了对有效治疗和管理药物的迫切需求。

市场概览
预测期 2027-2031
市场规模：2025年 85.7亿美元
市场规模：2031年 116.9亿美元
复合年增长率：2026-2031年 5.31%
成长最快的细分市场 医院药房
最大的市场 北美洲

儘管市场需求强劲，但主要品牌药专利到期给市场带来了巨大挑战。随之而来的是，大量价格低廉的学名药涌入市场，导致激烈的价格竞争，从而减少主要生产商的收入。这种财务压力可能会削弱企业对新药研发进行大规模投资的意愿，而这些新药研发对于市场的持续扩张至关重要。

市场驱动因素

环境污染物和烟草烟雾暴露量的增加是全球支气管炎治疗市场的主要驱动力，直接导致慢性呼吸系统疾病发生率上升。持续吸入烟草烟雾和空气中的粒状物会导致持续性支气管发炎和黏液分泌过多，需要长期药物治疗。这种因果关係确保了支气管炎治疗拥有稳定的患者群体，尤其是在污染严重的欠发达地区。根据世界卫生组织（世卫组织）2024年1月发布的《2000-2030年全球烟草使用趋势报告》，全球约有12.5亿成年人被认定为烟草使用者，构成了一个庞大的高危险群，他们极易患上慢性支气管炎，需要长期药物治疗。

同时，新型药物製剂和吸入技术的进步正在推动市场创新，与传统支气管扩张剂相比，这些药物疗效更佳。研发人员正日益专注于标靶生物製药和磷酸二酯酶抑制剂，这些药物作用于特定的发炎通路，进而提高患者依从性和临床疗效。 2024年6月，Verona Pharma发布新闻稿，宣布了一项重要的里程碑：该公司宣布，Otuvia（恩西芬特林）——20多年来首个具有全新作用机制的用于慢性阻塞性肺部疾病（COPD）维持治疗的吸入药物——已获得美国食品药品监督管理局（FDA）的核准。此外，这些先进治疗方法的商业性成功也显而易见。 2024年，赛诺菲报告称，其生物製药Dupixent上半年全球销售额达61亿欧元，凸显了新一代呼吸系统疗法的巨大盈利潜力。

市场挑战

全球支气管炎治疗市场正面临重大挑战，主要品牌药的专利到期是一大障碍。这使得价格低廉的学名药能够迅速进入市场。这种转变迫使原厂药生产商在激烈的价格竞争环境中展开角逐，儘管处方量依然很高，但现有药物的市场价值却在下降。由此导致的收入减少显着降低了製药公司的投资回报率，并直接阻碍了研发支气管疾病新治疗方法所需的巨额资本投入。

这项挑战的严峻性显而易见，因为低成本竞争对手占据的市场份额与其收入贡献不成比例。根据美国可及药品协会 (Association for Accessible Medicines) 2024 年的报告，学名药和生物类似药占美国所有处方笺的 90%，但仅占药品总支出的 12%。这种惊人的统计差异凸显了品牌药生产商难以获得盈利，进而阻碍了他们为推动市场发展而进行的新疗法创新投资。

市场趋势

在全球支气管炎治疗市场，将吸入型皮质类固醇、长效毒蕈碱受体拮抗剂和长效β2受体激动剂整合于单剂量吸入系统中的固定剂量三重吸入剂的使用正在迅速增长。这一趋势正在重塑维持治疗的基础，简化了复杂的用药方案，并解决了重症慢性支气管炎患者使用多种吸入剂联合联合治疗时依从性低的问题。这些简化的疗法在预防病情加重方面展现出卓越的临床效用，商业性应用正在加速超越传统的双联疗法。例如，葛兰素史克（GSK）于2025年2月发布的《2024年全年及第四季度报告》显示，其单吸入三联疗法Trelezy Ellipta的全球销售额同比增长27%，这表明简化治疗通讯协定的市场正在快速扩张。

同时，对于儘管接受了最大剂量药物治疗但症状仍然持续的患者，采用微创呼吸介入设备正成为重要的治疗趋势。这些基于设备的治疗方法，包括支气管成形术和液态氮冷冻疗法，提供了一种非药物机制，可以清除肥大的杯状细胞并减少慢性支气管炎特有的粘液过度分泌。这项进展标誌着治疗策略从单纯抑制症状转向针对气道阻塞潜在病理病理学的介入治疗。 2024年7月，CSA Medical在新闻稿中宣布，其RejuvenAir系统（专门用于治疗慢性支气管炎的冷冻手术设备）的SPRAY-CB III期临床试验已完成患者招募，该试验在美国和欧洲共招募了210名受试者。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球支气管炎治疗市场展望

  • 市场规模及预测
    • 按金额
  • 市占率及预测
    • 药物分类（抗生素、抗发炎药、支气管扩张剂、其他）
    • 依类型（急性支气管炎、慢性支气管炎）
    • 依最终用户（医院药局、零售药局、其他）划分
    • 按地区
    • 按公司（2025 年）
  • 市场地图

第六章：北美支气管炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 北美洲：国别分析
    • 我们
    • 加拿大
    • 墨西哥

第七章：欧洲支气管炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 欧洲：国别分析
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙

第八章：亚太地区支气管炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 亚太地区：国别分析
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲

第九章：中东和非洲支气管炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 中东与非洲：国别分析
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非

第十章：南美洲支气管炎治疗市场展望

  • 市场规模及预测
  • 市占率及预测
  • 南美洲：国别分析
    • 巴西
    • 哥伦比亚
    • 阿根廷

第十一章 市场动态

  • 促进因素
  • 任务

第十二章 市场趋势与发展

  • 併购
  • 产品发布
  • 近期趋势

第十三章：全球支气管炎治疗市场：SWOT分析

第十四章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的议价能力
  • 顾客权力
  • 替代品的威胁

第十五章 竞争格局

  • AstraZeneca PLC
  • Novartis AG
  • GSK PLC
  • Dr. Reddy's Laboratories Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc
  • Melinta Therapeutics Inc
  • Lupin Ltd
  • Cadila Pharmaceuticals Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

简介目录
Product Code: 18856

The Global Bronchitis Treatment Market is projected to expand from USD 8.57 Billion in 2025 to USD 11.69 Billion by 2031, reflecting a compound annual growth rate of 5.31%. This sector encompasses a range of pharmaceutical interventions, such as bronchodilators, anti-inflammatory agents, antibiotics, and mucolytics, all aimed at reducing bronchial inflammation and enhancing respiratory function. The market's growth is largely fueled by the rising prevalence of respiratory disorders attributed to aging populations worldwide, continued tobacco consumption, and increasing environmental pollution. Data from the International Pharmaceutical Federation in 2024 indicates that roughly 391 million individuals globally were living with chronic obstructive pulmonary disease, a major condition involving chronic bronchitis, highlighting the urgent and escalating demand for effective therapeutic management.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 8.57 Billion
Market Size 2031USD 11.69 Billion
CAGR 2026-20315.31%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

Despite this robust demand, the market encounters significant obstacles related to the expiration of patents for key branded therapeutics. The subsequent influx of cost-effective generic alternatives leads to intense pricing competition and a decline in revenue streams for major manufacturers. This financial strain can disincentivize substantial investment in the research and development of novel drug classes that are essential for continued market expansion.

Market Driver

Rising exposure to environmental pollutants and cigarette smoke serves as a primary driver for the Global Bronchitis Treatment Market, directly increasing the incidence of chronic respiratory conditions. Continuous inhalation of tobacco smoke and airborne particulates causes persistent bronchial inflammation and excessive mucus production, necessitating long-term pharmacological management. This causal link ensures a steady patient base for bronchitis therapeutics, particularly in developing regions with high pollution levels. According to the World Health Organization's 'Global Report on Trends in Prevalence of Tobacco Use 2000-2030' released in January 2024, approximately 1.25 billion adults globally were identified as tobacco users, creating a massive demographic susceptible to developing chronic bronchitis and requiring maintenance therapy.

Concurrently, the market is being revolutionized by advancements in novel drug formulations and inhalation technologies, which offer superior efficacy compared to traditional bronchodilators. Developers are increasingly focusing on targeted biologics and phosphodiesterase inhibitors that address specific inflammatory pathways, thereby improving patient compliance and clinical outcomes. A significant milestone was noted by Verona Pharma in a June 2024 press release, announcing FDA approval for Ohtuvayre (ensifentrine), the first inhaled product with a novel mechanism of action for COPD maintenance available in over 20 years. Furthermore, the commercial success of these advanced therapies is evident; Sanofi reported in 2024 that the biologic drug Dupixent generated global sales of €6.1 billion in the first half of the year, underscoring the lucrative potential of next-generation respiratory treatments.

Market Challenge

The Global Bronchitis Treatment Market faces a critical hurdle due to the patent expiration of key branded therapeutics, which triggers the immediate entry of cost-effective generic alternatives. This shift compels original manufacturers to compete in an environment characterized by intense pricing pressure, causing the market value of established drugs to fall even as prescription volumes remain high. The resulting erosion of revenue streams significantly reduces the return on investment for pharmaceutical companies, directly discouraging the substantial financial commitment required to discover and develop novel treatments for bronchial conditions.

The magnitude of this challenge is illustrated by the disproportionate market share held by lower-cost competitors compared to their revenue contribution. According to the Association for Accessible Medicines in 2024, generic and biosimilar medicines accounted for 90 percent of all prescriptions filled in the United States while comprising only 12 percent of total drug spending. This sharp statistical disparity demonstrates the difficulty branded manufacturers encounter in securing profitable returns, thereby hampering the investment necessary to drive the market forward with new therapeutic innovations.

Market Trends

The Global Bronchitis Treatment Market is experiencing a robust shift toward the increasing utilization of fixed-dose triple combination inhalers, which consolidate an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-agonist into a single administration system. This trend is fundamentally reshaping maintenance therapy by simplifying complex medication schedules, thereby resolving poor adherence issues associated with multi-inhaler regimens in patients with severe chronic bronchitis. The superior clinical utility of these streamlined therapies in preventing exacerbations has accelerated their commercial uptake over conventional dual therapies. For instance, GSK's 'Full-year and fourth quarter 2024' report from February 2025 noted that global sales of the single-inhaler triple therapy Trelegy Ellipta grew by 27 percent compared to the previous year, demonstrating the rapid market expansion of simplified treatment protocols.

Simultaneously, the adoption of minimally invasive interventional pulmonology devices is emerging as a critical trend for managing patients who remain symptomatic despite maximal pharmacological intervention. These device-based therapies, including bronchial rheoplasty and liquid nitrogen cryospray, offer a non-drug mechanism to ablate hyperplastic goblet cells and reduce the mucus hypersecretion that characterizes chronic bronchitis. This development marks a pivot toward procedural solutions that target the underlying pathophysiology of airway obstruction rather than merely suppressing symptoms. In July 2024, CSA Medical announced in a press release the successful completion of patient enrollment for the SPRAY-CB pivotal trial of the RejuvenAir System, a cryosurgical device specifically developed to treat chronic bronchitis, involving 210 subjects across the United States and Europe.

Key Market Players

  • AstraZeneca PLC
  • Novartis AG
  • GSK PLC
  • Dr. Reddy's Laboratories Ltd
  • Sanofi SA
  • Boehringer Ingelheim International GmbH
  • Pfizer Inc
  • Melinta Therapeutics Inc
  • Lupin Ltd
  • Cadila Pharmaceuticals Ltd

Report Scope

In this report, the Global Bronchitis Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bronchitis Treatment Market, By Class of Drugs

  • Antibiotics
  • Anti-inflammatory Drugs
  • Bronchodilator
  • Others

Bronchitis Treatment Market, By Type

  • Acute Bronchitis
  • Chronic Bronchitis

Bronchitis Treatment Market, By End User

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Bronchitis Treatment Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bronchitis Treatment Market.

Available Customizations:

Global Bronchitis Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bronchitis Treatment Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Class of Drugs (Antibiotics, Anti-inflammatory Drugs, Bronchodilator, Others)
    • 5.2.2. By Type (Acute Bronchitis, Chronic Bronchitis)
    • 5.2.3. By End User (Hospital Pharmacies, Retail Pharmacies, Others)
    • 5.2.4. By Region
    • 5.2.5. By Company (2025)
  • 5.3. Market Map

6. North America Bronchitis Treatment Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Class of Drugs
    • 6.2.2. By Type
    • 6.2.3. By End User
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bronchitis Treatment Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Class of Drugs
        • 6.3.1.2.2. By Type
        • 6.3.1.2.3. By End User
    • 6.3.2. Canada Bronchitis Treatment Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Class of Drugs
        • 6.3.2.2.2. By Type
        • 6.3.2.2.3. By End User
    • 6.3.3. Mexico Bronchitis Treatment Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Class of Drugs
        • 6.3.3.2.2. By Type
        • 6.3.3.2.3. By End User

7. Europe Bronchitis Treatment Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Class of Drugs
    • 7.2.2. By Type
    • 7.2.3. By End User
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bronchitis Treatment Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Class of Drugs
        • 7.3.1.2.2. By Type
        • 7.3.1.2.3. By End User
    • 7.3.2. France Bronchitis Treatment Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Class of Drugs
        • 7.3.2.2.2. By Type
        • 7.3.2.2.3. By End User
    • 7.3.3. United Kingdom Bronchitis Treatment Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Class of Drugs
        • 7.3.3.2.2. By Type
        • 7.3.3.2.3. By End User
    • 7.3.4. Italy Bronchitis Treatment Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Class of Drugs
        • 7.3.4.2.2. By Type
        • 7.3.4.2.3. By End User
    • 7.3.5. Spain Bronchitis Treatment Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Class of Drugs
        • 7.3.5.2.2. By Type
        • 7.3.5.2.3. By End User

8. Asia Pacific Bronchitis Treatment Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Class of Drugs
    • 8.2.2. By Type
    • 8.2.3. By End User
    • 8.2.4. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bronchitis Treatment Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Class of Drugs
        • 8.3.1.2.2. By Type
        • 8.3.1.2.3. By End User
    • 8.3.2. India Bronchitis Treatment Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Class of Drugs
        • 8.3.2.2.2. By Type
        • 8.3.2.2.3. By End User
    • 8.3.3. Japan Bronchitis Treatment Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Class of Drugs
        • 8.3.3.2.2. By Type
        • 8.3.3.2.3. By End User
    • 8.3.4. South Korea Bronchitis Treatment Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Class of Drugs
        • 8.3.4.2.2. By Type
        • 8.3.4.2.3. By End User
    • 8.3.5. Australia Bronchitis Treatment Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Class of Drugs
        • 8.3.5.2.2. By Type
        • 8.3.5.2.3. By End User

9. Middle East & Africa Bronchitis Treatment Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Class of Drugs
    • 9.2.2. By Type
    • 9.2.3. By End User
    • 9.2.4. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bronchitis Treatment Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Class of Drugs
        • 9.3.1.2.2. By Type
        • 9.3.1.2.3. By End User
    • 9.3.2. UAE Bronchitis Treatment Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Class of Drugs
        • 9.3.2.2.2. By Type
        • 9.3.2.2.3. By End User
    • 9.3.3. South Africa Bronchitis Treatment Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Class of Drugs
        • 9.3.3.2.2. By Type
        • 9.3.3.2.3. By End User

10. South America Bronchitis Treatment Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Class of Drugs
    • 10.2.2. By Type
    • 10.2.3. By End User
    • 10.2.4. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bronchitis Treatment Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Class of Drugs
        • 10.3.1.2.2. By Type
        • 10.3.1.2.3. By End User
    • 10.3.2. Colombia Bronchitis Treatment Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Class of Drugs
        • 10.3.2.2.2. By Type
        • 10.3.2.2.3. By End User
    • 10.3.3. Argentina Bronchitis Treatment Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Class of Drugs
        • 10.3.3.2.2. By Type
        • 10.3.3.2.3. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bronchitis Treatment Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. AstraZeneca PLC
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis AG
  • 15.3. GSK PLC
  • 15.4. Dr. Reddy's Laboratories Ltd
  • 15.5. Sanofi SA
  • 15.6. Boehringer Ingelheim International GmbH
  • 15.7. Pfizer Inc
  • 15.8. Melinta Therapeutics Inc
  • 15.9. Lupin Ltd
  • 15.10. Cadila Pharmaceuticals Ltd

16. Strategic Recommendations

17. About Us & Disclaimer